

Infectious Disease Endorsement Maintenance 2012: NQF-Endorsed® Maintenance Standards

Table of Submitted Measures

As of August 22, 2012

| Measure Number | Title | Description | Measure Steward |
|----------------|---|---|---|
| 0058 | Avoidance of antibiotic treatment in adults with acute bronchitis | The percentage of adults 18–64 years of age with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription. | National Committee for Quality Assurance (NCQA) |
| 0069 | Appropriate treatment for children with upper respiratory infection (URI) | Percentage of children 3 months to 18 years of age with a diagnosis of URI who were not dispensed an antibiotic medication. | National Committee for Quality Assurance (NCQA) |
| 0298 | Central line bundle compliance | Percentage of intensive care patients with central lines for whom all elements of the central line bundle are documented and in place. The central line bundle elements include: <ul style="list-style-type: none"> •Hand hygiene , •Maximal barrier precautions upon insertion •Chlorhexidine skin antisepsis •Optimal catheter site selection, with avoidance of the femoral vein for central venous access in patients 18 years and older •Daily review of line necessity with prompt removal of unnecessary lines | Institute for Healthcare Improvement |
| 0302 | Ventilator bundle (withdrawn from consideration of endorsement-request for retirement by developer) | Percentage of intensive care unit patients on mechanical ventilation at time of survey for whom all four elements of the ventilator bundle are documented and in place. The ventilator bundle elements are: <ul style="list-style-type: none"> •Head of bed (HOB) elevation 30 degrees or greater (unless medically contraindicated); noted on 2 different shifts within a 24 hour period •Daily “sedation interruption” and daily assessment of readiness to extubate; process includes interrupting sedation until patient follow commands and patient is assessed for discontinuation of mechanical ventilation; Parameters of discontinuation include: resolution of reason for intubation; inspired oxygen content roughly 40%; assessment of patients ability to defend airway after extubation due to heavy sedation; | Institute for Healthcare Improvement |

| Measure Number | Title | Description | Measure Steward |
|----------------|---|---|--|
| | | minute ventilation less than equal to 15 liters/minute; and respiratory rate/tidal volume less than or equal to 105/min/L(RR/TV< 105) •SUD (peptic ulcer disease) prophylaxis •DVT (deep venous thrombosis) prophylaxis | |
| 0393 | Hepatitis C: Testing for chronic hepatitis C- Confirmation of hepatitis C viremia | Percentage of patients aged 18 years and older with a diagnosis of hepatitis C seen for an initial evaluation who had HCV RNA testing ordered or previously performed. | American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI) |
| 0394 | Hepatitis C: Counseling regarding use of contraception prior to antiviral treatment | Percentage of female patients aged 18 to 44 years and all men aged 18 years and older with a diagnosis chronic hepatitis C who are receiving antiviral treatment who were counseled regarding contraception prior to the initiation of antiviral treatment. | American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI) |
| 0395 | Hepatitis C ribonucleic acid (RNA) testing before initiating treatment *paired with 0396 | Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative HCV RNA testing was performed within 6 months prior to initiation of antiviral treatment. | American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI) |
| 0396 | HCV genotype testing prior to treatment *paired with 0395 | Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom HCV genotype testing was performed prior to initiation of antiviral treatment. | American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI) |
| 0397 | Hepatitis C: Antiviral treatment prescribed | Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who were prescribed at a minimum peginterferon and ribavirin therapy within the 12 month reporting period. | American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI) |
| 0398 | Hepatitis C: HCV RNA testing at week 12 of treatment | Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative HCV RNA testing was performed at no greater than 12 weeks from initiation of antiviral treatment. | American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI) |
| 0399 | Hepatitis C: Hepatitis A vaccination *paired with 0400 | Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who have received at least one injection of hepatitis A vaccination, or who have documented immunity to hepatitis A. | American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI) |

| Measure Number | Title | Description | Measure Steward |
|----------------|--|--|--|
| 0400 | Hepatitis C: Hepatitis B vaccination *paired with 0399 | Percentage of patients aged 18 years and older with a diagnosis for hepatitis C who have received at least one injection of hepatitis B vaccination, or who have documented immunity to hepatitis B. | American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI) |
| 0401 | Hepatitis C: Counseling regarding risk of alcohol consumption | Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who were counseled regarding the risks of alcohol consumption at least once within the 12 month reporting period. | American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI) |
| 0403 | HIV/AIDS: Medical visit | Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS with at least two medical visits during the measurement year, with a minimum of 90 and 180 days between each visit. | National Committee for Quality Assurance (NCQA) |
| 0404 | HIV/AIDS: CD4 cell count or percentage performed | Percentage of patients aged six months or older with a diagnosis of HIV/AIDS, with a CD4 cell count or percentage performed at least once every 6 months. | National Committee for Quality Assurance (NCQA) |
| 0405 | HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) prophylaxis | Percentage of patients aged 6 weeks or older with a diagnosis of HIV/AIDS, who were prescribed pneumocystis jiroveci pneumonia (PCP) prophylaxis. | National Committee for Quality Assurance (NCQA) |
| 0406 | HIV/AIDS: Adolescent and adult patients who are prescribed potent antiretroviral therapy | Percentage of patients with a diagnosis of HIV/AIDS, with at least two visits during the measurement year, with at least 90 days between each visit: aged 13 years and older who have a history of a CD4 count=500cells/mm ³ ; aged 13 years and older who have a history of an AIDS-defining illness, regardless of CD4 count; or who are pregnant, regardless of CD4 count or age, who were prescribed potent antiretroviral therapy. | National Committee for Quality Assurance (NCQA) |
| 0407 | HIV/AIDS: HIV RNA control after six months of potent antiretroviral therapy | Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, who had at least two medical visits during the measurement year, with at least 90 days between each visit, who are receiving potent antiretroviral therapy*, who have a viral load <200 copies/mL after at least 6 months of potent antiretroviral therapy.* *Potent antiretroviral therapy is described as any antiretroviral therapy that has demonstrated optimal efficacy and results in durable suppression of HIV as shown by prior clinical trials. | National Committee for Quality Assurance (NCQA) |
| 0408 | HIV/AIDS: Tuberculosis (TB) screening | Percentage of patients aged 3 months and older with a diagnosis of HIV/AIDS, for whom there was documentation that a tuberculosis (TB) screening test was performed and | National Committee for Quality Assurance (NCQA) |

| Measure Number | Title | Description | Measure Steward |
|----------------|--|---|---|
| | | results interpreted (for tuberculin skin tests) at least once since the diagnosis of HIV infection. | |
| 0409 | HIV/AIDS: Sexually transmitted diseases- Screening for chlamydia, gonorrhea and syphilis | Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, who have received chlamydia, gonorrhea, and syphilis screenings at least once since the diagnosis of HIV infection. | National Committee for Quality Assurance (NCQA) |
| 0410 | HIV/AIDS: Sexually transmitted diseases- Syphilis screening (withdrawn from consideration of endorsement-this measure has been combined with measure 0409) | Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS for whom syphilis screening was performed during the measurement year | National Committee for Quality Assurance (NCQA) |
| 0411 | HIV/AIDS: Other infectious diseases-Hepatitis B screening (withdrawn from consideration of endorsement-request for retirement by developer) | Percentage of patients for whom Hepatitis B screening was performed at least once since the diagnosis of HIV infection or for whom there is documented immunity | National Committee for Quality Assurance (NCQA) |
| 0412 | HIV/AIDS: Hepatitis B vaccination | Percentage of patients aged six months and older with a diagnosis of HIV/AIDS, who have received at least one hepatitis B vaccination, or who have documented immunity. | National Committee for Quality Assurance (NCQA) |
| 0413 | HIV/AIDS: Screening for high risk sexual behaviors (withdrawn from consideration of endorsement-request for retirement by developer) | Percentage of patients, aged 13 years and older, who were screened for high risk sexual behaviors at least once within 12 months | National Committee for Quality Assurance (NCQA) |
| 0414 | HIV/AIDS: Other infectious diseases-Hepatitis C (withdrawn from consideration of | Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS for whom Hepatitis screening was performed at least once since the diagnosis of HIV infection, or for whom there is documented immunity | National Committee for Quality Assurance (NCQA) |

| Measure Number | Title | Description | Measure Steward |
|----------------|--|--|--|
| | endorsement-request for retirement by developer) | | |
| 0415 | HIV/AIDS: Screening for injection drug use (withdrawn from consideration of endorsement-request for retirement by developer) | Percentage of patients, aged 13 years and older, who were screened for injection drug use at least once within 12 months | National Committee for Quality Assurance (NCQA) |
| 0500 | Severe sepsis and septic shock: Management bundle | This measure will focus on patients aged 18 years and older who present with symptoms of severe sepsis or septic shock. These patients will be eligible for the 3 hour (severe sepsis) and/or 6 hour (septic shock) early management bundle. | Henry Ford Hospital |
| 0568 | Appropriate follow-up for patients with HIV (withdrawn from consideration of endorsement-request for retirement by developer) | To ensure that all members diagnosed with HIV receive at least annual testing for CD4 and at least biannual HIV RNA levels to monitor for disease activity | Health Benchmarks-IMS Health |
| 0584 | Hepatitis C: Viral load test | This measure identifies the percentage of patients with chronic Hepatitis C (HCV) who began HCV antiviral therapy during the measurement year and had HCV viral load testing 6 months prior to initiation of antiviral therapy. | Resolution Health, Inc. |
| 2079 | Medical visit frequency | Percentage of patients, regardless of age, with a diagnosis of HIV who had at least one medical visit in each 6-month period of the 24-month measurement period with a minimum of 60 days between medical visits. | Health Resources and Services Administration - HIV/AIDS Bureau |
| 2080 | Gap in medical visits | Percentage of patients, regardless of age, with a diagnosis of HIV who did not have a medical visit in the last 6 months of the measurement year. | Health Resources and Services Administration - HIV/AIDS Bureau |
| 2081 | Newly enrolled in medical care | Percentage of patients, regardless of age, with a diagnosis of HIV who were newly enrolled and had a medical visit in each of the 4-month periods in the measurement year. | Health Resources and Services Administration - HIV/AIDS Bureau |

| Measure Number | Title | Description | Measure Steward |
|-----------------------|--|---|--|
| 2082 | HIV viral load suppression | Percentage of patients, regardless of age, with a diagnosis of HIV with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year. | Health Resources and Services Administration - HIV/AIDS Bureau |
| 2083 | Prescription of HIV antiretroviral therapy | Percentage of patients, regardless of age, with a diagnosis of HIV prescribed antiretroviral therapy for the treatment of HIV infection during the measurement year. | Health Resources and Services Administration - HIV/AIDS Bureau |